NitroAlbmin - A non invasive biomarker of early stage nitro-oxidative stress
A non invasive biomarker of early stage nitro-oxidative stress : Nitrated Plasma Albumin
- First clinically validated marker of nitrative stress available
- Simple, specific, quick and sensitive (detection of nitroalbumin even in populations with low levels, such as newborns)
- Clinically validated in several pathologies
- Suitable for use with plasma, serum, cerebrospinal fluid and urine
- Antibodies suitable for use in cells and tissues by Western-blot and immunoprecipitation
Opportunités de marché
- Research and preclinical studies
- Clinical studies (diabetes, neurodegenerative diseases, inflammation, infectious diseases, respiratory diseases (COPD), cancer, toxicology, …)
- Follow up of treatment (i.e. neuroprotective strategies aiming at scavenging ONOO or preventing the generation of its precursors)
Stade de développement
- 1st generation ELISA (anti-nitrotyrosine mAb + anti-albumin-HRP pAb) developed and clinically validated on newborns suffering from asphyxia or hypoglycemia
- Anti-nitroalbumin mAbs (against the nitrated 138Tyr containing epitope of human albumin) generated to develop a second-generation ELISA
- Collaborative research
Patent application : WO/2009/112670
Chercheur / Laboratoire
Serge Bottari / Institute for advanced Biosciences (IAB)
Increased production of reactive oxygen (ROS) and reactive nitrogen species (RNS), and subsequent nitro-oxidative stress, is associated with many pathogical conditions such as neurodegenerative diseases, cancer, diabetes, respiratory, cardiovascular, infectious and inflammatory diseases.
Whereas numerous (> 70) markers of oxidative stress are available, there are so far no reliable assays allowing the investigation of nitrative stress in research and clinical practice.
Tyrosine nitration is among the earliest markers of nitro-oxidative stress. Detection of these early and reversible events may therefore allow for a better understanding of pathophysiological processes and for the early implementation and follow-up of treatments.
The present invention relates to the development of a quantitative immunoassay and reagents for a known well-characterized nitrated plasma protein, nitroalbumin. This biomarker has been clinically validated in perpartal hypoxia and neonatal hypoglycemia.
With the half-life of ONOO- being less than 1s in vivo, it is impossible to measure its concentration directly. Systemic nitro-oxidative stress can therefore only be determined by measuring the degree of nitration of a stable plasma protein with a sufficient half-life and a known number of nitration sites.
How it works:
- ELISA for
the quantitative determination of nitroalbumin in human plasma: robust and
highly sensitive method for monitoring nitroalbumin concentrations even in
populations which display low levels, such as newborns
- Affinity-purified anti-nitrotyrosine and anti-albumin antibodies warrant the specificity of the assay: lack of significant cross-reactivity with other tyrosine adducts, 5-nitrotryptophan, native human albumin, and aminotyrosine-albumin.
In addition to licensing, the technology is available through collaborative research opportunities with the inventors for further development such as:
- The development of a 2nd generation ELISA using
proprietary anti-nitroalbumin mAbs combined or not with anti-albumin Abs to
improve the linearity of the assay
- Clinical validation in relevant pathologies: COPD, neurodegenerative diseases diabetes, …